Atlas Reserve Precious Metals LLC is a Wyoming-registered precious metals dealer focused on transparent pricing, physical delivery options, and secure depository storage for self-directed retirement investors. The company provides access to IRS-eligible bullion products, allocated storage solutions, and rollover support services for qualified retirement accounts, founded on the principle that physical gold and silver should be accessible, understandable, and fairly priced for Americans seeking to diversify their retirement portfolios with tangible assets.

Cheyenne, Wyoming, United States, 21st May 2026 – Atlas Reserve Precious Metals LLC, a Wyoming-registered precious metals dealer, has announced the official launch of its physical gold and silver bullion platform designed for self-directed Gold IRAs and Silver IRAs. The company provides access to IRS-eligible gold and silver coins and bars, supported by transparent spot-plus-premium pricing and allocated storage through U.S.-based depositories.

The platform was developed to provide a straightforward process for individuals seeking to include physical precious metals within self-directed retirement account structures. Atlas Reserve supports rollovers from eligible retirement accounts, including traditional IRAs, Roth IRAs, and 401(k) plans, with dedicated support throughout the account transfer process.

“Atlas Reserve gives American investors a simple, transparent way to allocate a portion of their 401(k) or IRA into physical precious metals”

said Diren Tercanoglu, Director and Founder of Atlas Reserve Precious Metals LLC. 

“IRS-eligible gold and silver bullion at true low markups, combined with secure allocated storage and the flexibility of physical delivery – that is the foundation of what Atlas Reserve offers. The goal is to make real, physical assets accessible without the high fees or complexity that have historically made Gold IRAs difficult for everyday investors.”

Gold IRA and Silver IRA Platform Features

Atlas Reserve provides IRS-approved gold and silver coins and bars eligible for self-directed retirement accounts. Pricing follows a transparent spot-plus-premium structure with no undisclosed fees, offering investors clear visibility into premiums and transaction costs. The platform supports seamless rollover processing from 401(k)s, traditional IRAs, Roth IRAs, and other qualified plans. Storage is fully allocated and insured through leading U.S. depositories, with physical delivery available for investors who prefer direct possession.

401(k) to Gold IRA Rollover Guide

To support investors navigating the rollover process, Atlas Reserve has published a free educational resource covering eligibility requirements, IRS rules, custodian selection, and step-by-step rollover procedures. The guide is available at:

https://atlasreserve.global/ira/rollover-guide

About Atlas Reserve Precious Metals LLC

Atlas Reserve Precious Metals LLC is a Wyoming-registered precious metals dealer focused on transparent pricing, physical delivery options, and secure depository storage for self-directed retirement investors. The company provides access to IRS-eligible bullion products, allocated storage solutions, and rollover support services for qualified retirement accounts, founded on the principle that physical gold and silver should be accessible, understandable, and fairly priced for Americans seeking to diversify their retirement portfolios with tangible assets.

Website: https://atlasreserve.global

PR distributed by crmoonboy (crmoon): https://t.me/crmoon

Media Contact

Organization: Atlas Reserve Precious Metals LLC

Contact Person: Diren Tercanoglu

Website: https://atlasreserve.global/

Email:
admin@atlasreserve.global

Contact Number: +13076224606

City: Cheyenne

State: Wyoming

Country:United States

Release id:45242

The post Atlas Reserve Precious Metals Launches Transparent Gold IRA and Silver IRA Platform for Retirement Investors appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Niihara International, Inc. has launched a new corporate website and received SEC qualification of its Regulation A+ Tier 2 offering to support development and commercialization of therapies, including L‑glutamine for sickle cell disease and other unmet medical needs.

Irvine, California, United States, 21st May 2026– Niihara International, Inc. (“Niihara International” or the “Company”), today announced the launch of its new corporate website at www.niiharainternational.com and the qualification by the U.S. Securities and Exchange Commission (“SEC”) of the Company’s Regulation A+ Tier 2 offering of common stock. The Company is a pharmaceutical access company focused on expanding access to proven therapies for serious and underserved medical conditions.

The new website is designed to provide investors, patients, healthcare professionals, and other stakeholders with streamlined access to information about the Company’s business, product development plans, corporate governance and investor materials. The site features dedicated sections for corporate information, regulatory filings, and updates regarding Niihara International’s efforts to develop and commercialize innovative therapies, including its initial product candidate, a generic prescription-grade L‑glutamine oral powder for sickle cell disease. 

Niihara International’s Regulation A+ Tier 2 offering has been qualified by the SEC pursuant to the Company’s Offering Circular, which is available on the SEC’s EDGAR system. Under the qualified offering, the Company is offering shares of its common stock on a “best efforts” basis, with the proceeds intended to fund product development, clinical, regulatory and commercialization activities, as well as general corporate purposes. 

The Offering Circular and related information about the offering can be accessed by visiting the SEC’s website and searching for Niihara International, Inc. (CIK 0002062360) or via the Company’s own website via the link to its subscription portal provided below. Prospective investors are urged to carefully review the Offering Circular, including the section titled “Risk Factors,” and all other documents incorporated by reference before making any investment decision.

“This is an important milestone for Niihara International as we advance our strategy to develop and deliver therapies for patients with serious unmet medical needs,” said Founder and CEO Yutaka Niihara. “The launch of our new website and the qualification of our Regulation A+ Tier 2 offering provide a foundation to communicate more effectively with investors and partners as we seek to execute on our growth plans.” 

The securities described in the Offering Circular are being offered pursuant to Regulation A under the Securities Act of 1933, as amended. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of securities will be made only by means of the Offering Circular and related subscription materials.

About Niihara International, Inc.

Niihara International, Inc., incorporated in California in 2023, is a development-stage biopharmaceutical company focused on the development, commercialization and distribution of innovative therapies. The Company is also focused on expanding access to proven therapies for serious and underserved medical conditions.

 The Company’s initial product is a generic prescription-grade L‑glutamine oral powder designed to reduce acute complications associated with sickle cell disease in patients ages five years and older. For more information, please visit www.niiharainternational.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the Company’s business strategy, development plans, product candidates, potential markets, and the anticipated use of proceeds of the Regulation A+ Tier 2 offering. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described under “Risk Factors” in the Offering Circular and in other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and Niihara International, Inc. undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date hereof. 

Offering Portal Administrator
Glass Box Law, Inc.
Offering Portal Website:  https://glassboxlaw.com/portal/niihara-international-inc

Advancing Access to Essential Therapies for Patients with Unmet Medical Needs

Media Contact

Organization: Niihara International, Inc.

Contact Person: Maurice Bethea

Website: https://niiharainternational.com/

Email:
mbethea@niiharainternational.com

City: Rolling Hills Estates

State: California

Country:United States

Release id:45263

The post Niihara International Announces Launch of Corp. Website and SEC Qualification of Reg. A Offering appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

This Enterprise Unveils Industrial High-Purity Lipid Raw Material Product Portfolio for Global Fine Chemical Clients

Guangzhou, Guangdong, China, 21st May 2026 – Guangzhou Hanfang Pharmaceutical Company Limited. (a subsidiary of Guangzhou Pharmaceutical Holdings Limited) today announced updates to its industrial lipid raw material product portfolio and global service upgrades. The company’s offerings include industrial high-purity egg yolk lecithin, medium-chain triglycerides, and soybean oil (general-purpose raw material), tailored to meet industrial production requirements across multiple regions. Adopting a comprehensive business model encompassing direct sales, distribution, custom processing, and technical support, the enterprise serves over 1,000 clients worldwide with a business network spanning more than 20 countries and regions, further expanding its global fine chemical supply chain footprint.

Core Product Portfolio and Technical Services

Guangzhou Baiyunshan Hanfang Pharmaceutical provides products and services tailored for industrial fine chemical enterprises and related industries:

• Industrial High-Purity Lipid Raw Materials: Supplies industrial high-purity egg yolk lecithin, medium-chain triglycerides, and soybean oil (general-purpose raw material), serving as core components for emulsifiers, cosolvents, and industrial energy additive raw materials, complying with process standards for industrial production scenarios.
• Customization and Technical Support: Delivers customized solutions for exclusive raw material formulation needs, including compliant adjustments to component ratios and performance parameters; the technical team provides end-to-end guidance on production process applications.
• Comprehensive Business Model: Covers direct sales, authorized distribution, custom processing, and technical services, meeting diverse needs from standard orders to customized projects.

Global Compliance and Quality Standards

The enterprise has established operational and quality systems aligned with international fine chemical supply chain norms. Its production base in Conghua, Guangzhou, adopts fully controlled end-to-end processes to ensure consistent product quality. Products are sold across Asia, Europe, and other regions, with efficient delivery enabled by mature logistics channels.

Supply and Service Information

Products are available globally through the direct sales team and authorized distributors. Orders are accepted from industrial fine chemical enterprises and related manufacturers, with standard production lead times provided. Custom processing services are available for premium clients, alongside formulation technical consultations. Clients may inquire via the official website or regional sales representatives.

“We focus on ensuring the stability of the fine chemical supply chain, with deep expertise in the lipid raw material sector,” said Chen Shiqi, Project Manager at Guangzhou Baiyunshan Hanfang Pharmaceutical. “We are committed to delivering stable, reliable products and technical support to meet the evolving needs of our global clients.”

Industry Background and Strategic Direction

Industry data indicates sustained growth in global demand for high-quality industrial lipid raw materials, driven primarily by the expansion of global fine chemical production capacity and the need for supply chain resilience. As a member enterprise of Guangzhou Pharmaceutical Holdings Limited, Baiyunshan Hanfang closely follows trends in the fine chemical supply chain industry, focusing on product stability and global technical services to support the growth of clients worldwide.

Future Plans

Guangzhou Baiyunshan Hanfang Pharmaceutical will continue to increase investment in production capacity and product R&D, with plans to expand its global distribution network, upgrade technical service systems for international clients, and prioritize meeting the diverse production needs of core markets.

About Guangzhou Hanfang Pharmaceutical Company Limited

Founded in 1998 and headquartered in Guangzhou, Guangzhou Hanfang Pharmaceutical Company Limited employs more than 330 people across production, R&D, quality control, and administration. The enterprise specializes in industrial fine chemical raw materials, lipid raw materials, and supporting technical services, with products sold in over 20 countries and regions. It holds multiple patents for lipid processing technologies, with its Conghua production base serving as the core production hub. The enterprise’s mission is “stable supply, technical collaboration, empowering the global fine chemical industry.”
For more information, please visit the official website: https://www.byshanhanfang.com/

Media Contact

Organization: Guangzhou Hanfang Pharmaceutical Company Limited

Contact Person: Ms. Chen Shiqi

Website: https://www.byshanhanfang.com/

Email: Send Email

Contact Number: +8613427652966

Address:No. 8 Wenquan Avenue, Wenquan Town, Conghua District, Guangzhou Guangdong Province, P.R. China

City: Guangzhou

State: Guangdong

Country:China

Release id:45292

The post Baiyunshan Hanfang Pharmaceutical Releases Technical Progress on Industrial High-Purity Lipid Raw Materials appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section